Rep. Gilbert Cisneros Buys Vaxcyte (PCVX) Stock
Congressman Gilbert Cisneros purchased shares of Vaxcyte, Inc. valued between $1,001 and $15,000.
Reviewed by automated data checks against the source filing. How we make and check alerts
Rep. Gilbert Cisneros bought between $1,001 and $15,000 of Vaxcyte, Inc. ($PCVX) stock on May 12, 2026. The trade was disclosed in a STOCK Act periodic transaction report filed June 9, 2026.
Since the trade, $PCVX is down 9.7% after 1 week, down 12.5% after 1 month and up 17.8% to date (from the $54.03 close on May 12, 2026).
Financial Disclosure Report
Clerk of the House of Representatives • Legislative Resource Center • B81 Cannon Building • Washington, DC 20515
Filer Information
- Name:
- Rep. Gilbert Cisneros (D-CA)
- Status:
- Member — House
- State/District:
- CA-31
Filing Information
- Filing Type:
- Periodic Transaction Report
- Filing Year:
- 2026
- Filing Date:
- Jun 9, 2026
Schedule B: Transactions
| Asset | Transaction | Date | Amount |
|---|---|---|---|
| Vaxcyte, Inc. ($PCVX) | Buy | May 12, 2026 | $1,001 - $15,000 |
Summary of the filed report, not the original document. Find the original: House financial disclosure search
PCVX
Vaxcyte, Inc.
Key Points
- Gilbert Cisneros, a member of the House, bought Vaxcyte, Inc. shares valued between $1,001 and $15,000, reported on June 9, 2026.
- Vaxcyte, Inc. shares are trading at $47.46 with a market cap of $6.85 billion and a beta of 1.242.
- Institutional investors like Janus Henderson and FMR LLC have also increased their stakes in Vaxcyte recently.
Get $PCVX trade alerts by text
We text you when insiders, Congress or big funds trade $PCVX. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Vaxcyte, Inc. alert may contain errors. Disclosures
On June 9, 2026, Congressman Gilbert Cisneros disclosed a purchase of Vaxcyte, Inc. shares valued between $1,001 and $15,000. This transaction was reported after the trade, which took place on May 12, 2026. Cisneros, a member of the House of Representatives, showed interest in the biotechnology company that is currently trading at $47.46 per share.
Gilbert Cisneros vs. the S&P 500
Hypothetical returns from Gilbert Cisneros's disclosed trades, not real profit or advice. How we model this.
Other Institutional Activity in Vaxcyte
In addition to Cisneros's purchase, several institutional investors have made moves with Vaxcyte stock. Janus Henderson Group PLC grew its holdings by 3,188,687 shares, ending with 16,575,875 shares valued at approximately $960.2 million. FMR LLC also increased its position by 2,658,347 shares, bringing its total to 16,492,861 shares worth about $958.4 million. T. Rowe Price Investment Management, Inc. added 829,684 shares, now holding 12,126,017 shares valued at $704.6 million.
Vaxcyte, Inc. Stock Down 14.7%
Vaxcyte, Inc. (NasdaqGS: PCVX) is trading at $47.46, with a market capitalization of $6.85 billion. The company has a forward P/E ratio that is not meaningful as it isn't currently profitable. Its beta, a measure of volatility, stands at 1.242. Over the past year, the stock has ranged from a low of $29.08 to a high of $65.00. The 50-day moving average is $54.48, while the 200-day moving average is $48.67. Vaxcyte maintains a strong financial position with a current ratio of 7.49 and a quick ratio of 7.18.
Recent Earnings
Vaxcyte reported its latest earnings on May 6, 2026. The company is still in the clinical stage and has not yet generated revenue. Its earnings per share were negative at -$6.89, reflecting ongoing investment in research and development. Vaxcyte's return on equity is -30.55%, indicating the challenges of funding its innovative vaccine pipeline.
Insider Buying and Selling at Vaxcyte, Inc.
Several insiders have been active in trading Vaxcyte shares. Jim Wassil, the Chief Operating Officer, sold 2,250 shares on June 1, 2026, at an average price of $49.52, as part of a planned sale. Previously, Wassil sold additional shares on May 1 and April 1. Elvia Cowan, SVP of Finance & CAO, also executed trades, selling 3,000 shares on April 7 at $60.00, while buying 3,000 shares at $25.92 on the same day.
Analysts Set New Price Targets
Analysts remain optimistic about Vaxcyte's potential. On February 26, 2026, BTIG maintained a buy rating with a price target of $89. Guggenheim reiterated its buy rating with a target of $116 on February 2, 2026. The consensus among analysts is a strong buy, with a mean price target of $109, based on nine analyst opinions.
About Vaxcyte, Inc.
Vaxcyte, Inc. is a biotechnology company focused on developing vaccines to prevent bacterial infections. Headquartered in San Carlos, California, the company is led by CEO Grant E. Pickering. Vaxcyte's lead product is VAX-24, a pneumococcal conjugate vaccine aimed at preventing invasive pneumococcal disease. The company is also developing other vaccine candidates targeting various bacterial pathogens.
Bottom Line
Gilbert Cisneros's purchase of Vaxcyte shares highlights ongoing interest in the company's potential. Vaxcyte is a clinical-stage biotech firm with a promising vaccine pipeline, though it remains unprofitable. Institutional investors and analysts show strong interest, reflecting confidence in Vaxcyte's future prospects. Remember, these trades are disclosed after the fact and may not reflect current positions.
Related Filing Alerts
Source: Gilbert Cisneros's STOCK Act disclosure on $PCVX (May 12, 2026). Find the original filing: House financial disclosure search. Written by software, not financial advice. How we make alerts